Cancer Therapeutics-Related Cardiac Dysfunction　― Insights From Bench and Bedside of Onco-Cardiology ―

DOI Web Site Web Site PubMed 被引用文献6件 参考文献54件 オープンアクセス
  • Kadowaki Hiroshi
    Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
  • Akazawa Hiroshi
    Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
  • Ishida Junichi
    Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
  • Komuro Issei
    Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo

この論文をさがす

抄録

<p>Improvements in the long-term survival of cancer patients have led to growing awareness of the clinical importance of cancer therapeutics-related cardiac dysfunction (CTRCD), which can have a considerable effect on the prognosis and quality of life of cancer patients and survivors. Under such circumstances, onco-cardiology/cardio-oncology has emerged as a new discipline, with the aim of best managing cardiovascular complications, including CTRCD. Despite the recent accumulation of epidemiological and clinical information regarding CTRCD, the molecular mechanisms underlying the pathogenesis of CTRCD by individual drugs remain to be determined. To achieve the goal of preventing cardiovascular complications in cancer patients and survivors, it is important to elucidate the pathogenic mechanisms and to establish diagnostic strategies with risk prediction and mechanism- and evidence-based therapies against CTRCD.</p>

収録刊行物

  • Circulation Journal

    Circulation Journal 84 (9), 1446-1453, 2020-08-25

    一般社団法人 日本循環器学会

被引用文献 (6)*注記

もっと見る

参考文献 (54)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ